Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-T cells during killing of glioma cells in vitro.

BACKGROUND

Chimeric antigen receptor T cell therapy has limited efficacy in the treatment of glioma due to the blood-brain barrier and T cell exhaustion. Enhancement with rabies virus glycoprotein (RVG29) has shown improved brain-related efficacy.

METHODS

In this study, we developed CD70R CAR-T cells by modifying anti-CD70 CAR-T cells with RVG29 and tested their tumor-killing ability in vitro.

RESULTS

Transcriptomic profiling via RNA-seq revealed the activated signaling pathways in modified CD70R CAR-T cells. These cells displayed effective in vitro cytotoxicity against CD70+; glioma cells, furthermore, co-culture with glioma cells promoted the expansion of quiescent CD70R CAR-T cells.

CONCLUSION

The RVG29 modification enhances CAR-T therapy for brain tumors and holds promise for treating glioma.